The short- and long-term safety of 5-aminosalicylate products in the treatment of ulcerative colitis

Reviews in Gastroenterological Disorders

Volumn 4, Issue 2, 2004, Pages 86-91

  Baker, Daniel E ^a   Kane, Sunanda ^b  

^a WASHINGTON STATE UNIVERSITY   (United States)

^b UNIVERSITY OF CHICAGO   (United States)

Author keywords

5 aminosalicylic acid; Balsalazide; Mesalamine; Olsalazine; Sulfasalazine

Indexed keywords

BALSALAZIDE; EUDRAGIT; FOLIC ACID; MESALAZINE; OLSALAZINE; PRODRUG; SALAZOSULFAPYRIDINE; SULFAPYRIDINE; AMINOSALICYLIC ACID DERIVATIVE; PHENYLHYDRAZINE DERIVATIVE;

ABDOMINAL PAIN; DIARRHEA; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG FORMULATION; DRUG HYPERSENSITIVITY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; HEADACHE; HUMAN; LOW BIRTH WEIGHT; MALE INFERTILITY; NAUSEA; OLIGOSPERMIA; PREMATURE LABOR; REVIEW; SIDE EFFECT; ULCERATIVE COLITIS; VOMITING; ADOLESCENT; ADULT; CHILD; CLINICAL TRIAL; COMPARATIVE STUDY; DOSE RESPONSE; DRUG ADMINISTRATION; DRUG LABELING; FEMALE; MALE; MIDDLE AGED; POSTMARKETING SURVEILLANCE; SENSITIVITY AND SPECIFICITY;

ADOLESCENT; ADULT; AMINOSALICYLIC ACIDS; CHILD; CLINICAL TRIALS; COLITIS, ULCERATIVE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; DRUG LABELING; FEMALE; HUMANS; MALE; MESALAMINE; MIDDLE AGED; PHENYLHYDRAZINES; PRODUCT SURVEILLANCE, POSTMARKETING; SENSITIVITY AND SPECIFICITY; SULFASALAZINE;

EID: 2942642437     PISSN: 1533001X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (37)

1. Riley SA. What dose of 5-aminosalicylic acid (mesalamine) in ulcerative colitis? Gut. 1998; 42:761-763.
2. Kane SV, Bjorkman DJ. The efficacy of oral 5-ASAs in the treatment of active ulcerative colitis: a systematic review. Rev Gastroenterol Disord. 2003;3:210-218.
3. Prakash A, Spencer CM. Balsalazide. Drugs. 1998;56:83-89.
4. Chan RP, Pope DJ, Gilbert AP, et al. Studies of two novel sulfasalazine analogs, ipsalazide and balsalazide. Dig Dis Sci. 1983;28:609-615.
5. Klotz U. Clinical pharmacokinetics of sulphasalazine, its metabolites and other prodrugs of 5-aminosalicylic acid. Clin Pharmacokinet. 1985;10:285-302.
6. McIntyre PB, Rodrigues CA, Lennard-Jones JE, et al. Balsalazide in the maintenance treatment of patients with ulcerative colitis: a double-blind comparison with sulphasalazine. Aliment Pharmacol Ther. 1988;2:237-243.
7. Sutherland L, Roth D, Beck P, et al. Oral 5-aminosalicylic acid for maintenance of remission in ulcerative colitis. Cochrane Database Syst Rev. 2002;(4):CD000544.
8. Wickersham RM, ed. Drug Facts and Comparisons. St. Louis: Facts & Comparisons, 2004.
9. Brunner M, Assandri R, Kletter K, et al. Gastrointestinal transit and 5-ASA release from a new mesalazine extended-release formulation. Aliment Pharmacol Ther. 2003; 17:395-402.
10. Brogden RN, Sorkin EM. Mesalazine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in chronic inflammatory bowel disease. Drugs. 1989; 38:500-523.
11. Riley SA, Mani V, Goodman MJ, et al. Comparison of delayed release 5 andinosalicylic acid (mesalazine) and sulfasalazine in the treatment of mild to moderate ulcerative colitis relapse. Gut. 1988;29:669-674.
12. Nugent SG, Kumar D, Rampton DS, Evans EF. Intestinal luminal pH in inflammatory bowel disease: possible determinants and implications for therapy with aminosalicylates and other drugs. Gut. 2001;48:571-577.
13. Brunner M, Greinwald R, Metter K, et al. Gastrointestinal transit and release of 5-aminosalicylic acid from 153Sm-labelled mesalazine pellets vs. tablets in male healthy volunteers. Aliment Pharmacol Ther. 2003; 17:1163-1169.
14. Sandborn WJ, Hanauer SB. Systemic review: the pharmacokinetic profiles of oral mesalamine formulations and mesalamine pro-drugs used in the management of ulcerative colitis. Aliment Pharmacol Ther. 2003;17:29-42.
15. Hanauer SB, Regalli G, Verst-Brasch C. Safety of long-term mesalamine I patients with inflammatory bowel disease [abstract]. Am J Gastroenterol. 1996;91:A343.
16. Hanauer SB, Verst-Brasch C, Regalli G. Renal safety of long-term mesalamine therapy in inflammatory bowel disease [abstract]. Gastroenterology. 1997;112:A991.
17. Loftus EV Jr, Kane SV, Bjorkman D. Systematic review: short-term adverse effects of 5-aminosalicylic acid agents in the treatment of ulcerative colitis. Aliment Pharmacol Ther. 2004; 19:179-189.
18. Sutherland LR, Roth DE, Beck PL. Alternatives to sulfasalazine: a meta-analysis of 5-ASA in the treatment of ulcerative colitis. Inflamm Bowel Dis. 1997;3:65-78.
19. Sandborn WJ, Feagan BG. Review article: mild to moderate Crohn's disease-defining the basis for a new treatment algorithm. Aliment Pharmacol Ther. 2003;18:263-277.
20. Ishaq S, Green JRB. Tolerability of aminosalicylates in inflammatory bowel disease. BioDrugs. 2001;15:339-349.
21. Ransford RA, Langman MJ. Sulphasalazine and mesalazine: serious adverse reactions re-evaluated on the basis of suspected adverse reaction reports to the Committee on Safety of Medicines. Gut. 2002;51:536-539.
22. Marteau P, Nelet F, Le Lu M, Devaux C. Adverse events in patients treated with 5-aminosalicylic acid: 1993-1994 pharmacovigilance report for Pentasa in France. Aliment Pharmacol Ther. 1996;10:949-956.
23. Christensen LA, Jacobsen BA. 5-aminosalicylic acid derivatives. Clinical and pharmaceutical evaluation. Neth J Med. 1989;35:S3-S10.
24. Giaffer MH, O'Brien CJ, Holdsworth CD. Clinical tolerance to three 5-aminosalicylic acid releasing preparations in patients with inflammatory bowel disease intolerant or allergic to sulphasalazine. Aliment Pharmacol Ther. 1992; 6:51-59.
25. Kirschner BS, Verst-Brasch C, Regalli G, et al. Long-term safety profile of compassionate-use mesalamine in children [abstract]. Am J Gastroenterol. 1998;93:A329.
26. McIntyre PB, Lennard-Jones JE. Reversal with balsalazide of infertility caused by sulphasalazine. Br Med J. 1984;288:1652-1653.
27. Riley SA, Lecarpentier J, Mani V, et al. Sulphasalazine induced seminal abnormalities in ulcerative colitis: results of mesalazine substitution. Gut. 1987;28:1008-1012.
28. Norgard B, Forager K, Pedersen L. Birth outcome in women exposed to 5-ASA during pregnancy: a Danish cohort study. Gut. 2003; 52:243-247.
29. Briggs GG, Freeman RK, Yaffe SJ, eds. Drugs in Pregnancy and Lactation: A Reference Guide to Fetal and Neonatal Risk. 6th ed. Philadelphia: Lippincott Williams & Wilkins, 2002.
30. Nørgård B, Puho E, Pedersen L, et al. Risk of congenital abnormalities in children born to women with ulcerative colitis: a population-based, case-control study. Am J Gastroenterol. 2003;98:2006-2010.
31. Ferrero S, Ragni N. Inflammatory bowel disease: management issues during pregnancy. Arch Gynecol Obstet. 2003 Apr 30 [Epub ahead of print].
32. Diav-Citrin O, Park YH, Veerasuntharam G, et al. The safety of mesalamine in human pregnancy: a prospective controlled cohort study. Gastroenterology. 1998;114:23-28.
33. Subhani JM, Hamiliton MI. Review article: the management of inflammatory bowel disease during pregnancy. Aliment Pharmacol Ther. 1998;12:1039-1053.
34. Connell W, Miller A. Treating inflammatory bowel disease during pregnancy: risks and safety of drug therapy. Drug Saf. 1999;21:311-323.
35. Czeizel AE, Toth M, Rockenbauer M. Population-based case-control study of folic acid supplementation during pregnancy. Teratology. 1996;53:345-351.
36. Klotz U, Harings-Kaim A. Negligible excretion of 5-aminosalicylic acid in breast milk. Lancet. 1993;342:618-619.
37. American Academy of Pediatrics Committee on Drugs. The transfer of drugs and other chemicals into human milk. Pediatrics. 2001;108:776-789.